Key information

🔎 Fund Overview

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture, and commercialization of products that address unmet patient needs, with a focus on the treatment of pulmonary hypertension (PH). The Company operates, through its wholly owned subsidiaries, Liquidia Technologies, Inc., and Liquidia PAH, LLC. It conducts research, development, and manufacturing of products by applying its expertise in cardiopulmonary diseases and its PRINT technology, a particle engineering platform that enables the production of uniform drug particles designed to improve the safety, efficacy, and performance of a range of therapies. Its lead product candidate is YUTREPIA for the treatment of pulmonary arterial hypertension (PAH). YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low resistance dry-powder inhaler (DPI).